Kinesin 5A / KIF5A, Polyclonal Antibody

Anti-Kinesin 5A / KIF5A Antibody (Internal) IHC-plus; KIF5A; D12S1889; Kinesin 5A; KIF5A variant protein; Kinesin family member 5A; Kinesin heavy chain isoform 5A; SPG10; MY050; Neuronal kinesin heavy chain; NKHC; NKHC1; Human Kinesin 5A; KIF5A

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

a 20 amino acid peptide from near the center of human KIF5

Immunoaffinity Purified

PBS, 0.02% sodium azide.

1 mg/ml (lot specific)

Short term 4 degree C, long term aliquot and store at -20 degree C, avoid freeze thaw cycles. Store undiluted.

Small volumes of anti-Kinesin 5A antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Immunohistochemistry (IHC - Paraffin), Immunocytochemistry (ICC), Western Blot (WB), ELISA (EIA)

ELISA, ICC, IHC-P (5 ug/ml), WB (0.5 - 1 ug/ml)
Usage: Immunohistochemistry: was validated for use in immunohistochemistry on a panel of 21 formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with the primary anti...

Anti-KIF5A antibody IHC of human brain, cortex. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml.

Immunofluorescence of KIF5 in K562 cells with KIF5 antibody at 20 ug/ml.

Immunocytochemistry of KIF5 in K562 cells with KIF5 antibody at 5 µg/ml.

Western blot of KIF5 in K562 cell lysate with KIF5 antibody at (A) 0.5 and (B) 1 ug/ml.

117,378 Da

kinesin family member 5A

kinesin heavy chain isoform 5A; KIF5A variant protein; neuronal kinesin heavy chain; kinesin heavy chain neuron-specific 1; kinesin, heavy chain, neuron-specific

Kinesin heavy chain isoform 5A

NKHC1; NKHC  [Similar Products]

KIF5A_HUMAN

This gene encodes a member of the kinesin family of proteins. Members of this family are part of a multisubunit complex that functions as a microtubule motor in intracellular organelle transport. Mutations in this gene cause autosomal dominant spastic paraplegia 10. [provided by RefSeq, Jul 2008]

KIF5A: Microtubule-dependent motor required for slow axonal transport of neurofilament proteins (NFH, NFM and NFL). Defects in KIF5A are the cause of spastic paraplegia autosomal dominant type 10 (SPG10). An inherited degenerative spinal cord disorder characterized by a slow, gradual, progressive weakness and spasticity (stiffness) of the legs. Rate of progression and the severity of symptoms is quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Belongs to the kinesin-like protein family. Kinesin subfamily.

Protein type: Microtubule-binding; Motor

Chromosomal Location of Human Ortholog: 12q13.13

Cellular Component: microtubule; kinesin complex; membrane; perinuclear region of cytoplasm; cytosol

Molecular Function: protein binding; plus-end-directed microtubule motor activity; microtubule binding; ATPase activity; motor activity; ATP binding

Biological Process: synaptic transmission; axon guidance; protein localization; metabolic process; antigen processing and presentation of exogenous peptide antigen via MHC class II; cytoskeleton-dependent intracellular transport; blood coagulation; microtubule-based movement

Disease: Spastic Paraplegia 10, Autosomal Dominant

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.